Different Gene Therapies Fortreatment of Hemophilia A
DOI:
https://doi.org/10.54097/nbq15h90Keywords:
Gene therapy, Crisper-cas9, TALENs, ZFNs, Hemophilia A.Abstract
According to US Center for Disease Control and Prevention, there are 12 per 100000 males born with hemophilia A in US, and there are 400 male babies born with hemophilia A per year. Hemophilia A is type of disease that is inherited with X-linked recessive that have mutation in Factor VII gene. Recently, there are types of gene therapies success in hepatic vivo gene transferring. In this review, this paper will discuss three types of gene therapies for hemophilia A which are Zinc Finger Nucleases (ZFNs) and Transcription Activator Factors (TALENs) and CRISPER Cas9. ZFNs using the zinc finger DNA binding array in conjunction with FoKI cleavage nucleases domain to target and cleave to trigger the DNA repairing. In TALENs researchers induced pluripotent stem cells (iPSCs) derived by TALENickases to target the FVIII site. The latest research is using CRISPR Cas9 as a gene editing method to treat hemophilia A. The researchers used this method to repair the mutated gene so that the FVIII factor could be expressed normally. The paper also explains the current methods and process of delivery in gene therapy and shows the pros and cons of each. In conclusion, this paper express our prospects for future research about gene therapies.
Downloads
References
Urnov, F. D., Rebar, E. J., Holmes, M. C., Zhang, H. S., & Gregory, P. D. (2010). Genome. editing with engineered zinc finger nucleases. Nature Reviews Genetics, 11(9), 636–646.
Shin, J. H., Lee, J., Jung, Y. K., Kim, K. S., Jeong, J., & Choi, D. (2022). Therapeutic. applications of gene editing in chronic liver diseases: an update. BMB Reports, 55(6), 251–258.
Urnov, F. D., Miller, J. C., Lee, Y.-L., Beausejour, C. M., Rock, J. M., Augustus, S., Jamieson, A. C., Porteus, M. H., Gregory, P. D., & Holmes, M. C. (2005). Highly efficient endogenous human gene correction using designed zinc-finger nucleases. Nature, 435(7042), 646–651.
O’Connor, T. P., & Crystal, R. G. (2006). Genetic medicines: treatment strategies for hereditary disorders. Nature Reviews Genetics, 7(4), 261–276.
Lee, H. J., Kweon, J., Kim, E., Kim, S., & Kim, J.-S. (2011). Targeted chromosomal. duplications and inversions in the human genome using zinc finger nucleases. Genome Research, 22(3), 539–548.
Wu, Y., Hu, Z., Li, Z., Pang, J., Feng, M., Hu, X., Wang, X., Lin-Peng, S., Liu, B., Chen, F., Wu, L., & Liang, D. (2016). In situ genetic correction of F8 intron 22 inversion in hemophilia A patient-specific iPSCs. Scientific Reports, 6(1).
Anguela, X. M., Sharma, R., Doyon, Y., Wechsler, T., Paschon, D. E., Davidson, R. J., Zhou, S., Gregory, P. D., Holmes, M. C., Rebar, E. J., & High, K. A. (2013). ZFN Mediated Targeting of Albumin “Safe Harbor” Results in Therapeutic Levels of Human Factor VIII in a Mouse Model of Hemophilia A. Blood, 122(21), 720–720.
Jia, B., Chen, S.-M., Zhao, Z., Liu, P., Cai, J., Qin, D., Du, J., Wu, C. W., Chen, Q., Cai, X., Zhang, H., Yu, Y., Pei, D., Zhong, M., & Pan, G. (2014). Modeling of hemophilia A using patient-specific induced pluripotent stem cells derived from urine cells. 108(1), 22–29.
Park, C.-Y.., Kim, J., Kweon, J., Son, J. S., Lee, J. S., Yoo, J.-E.., Cho, S.-R.., Kim, J.-H.., Kim, J.-S.., & Kim, D.-W. (2014). Targeted inversion and reversion of the blood coagulation factor 8 gene in human iPS cells using TALENs. Proceedings of the National Academy of Sciences, 111(25), 9253–9258.
Nelwan, M. (2017, August 5). Hemophilia A and Induced Pluripotent Stem Cells. Papers.ssrn.com.
van den Berg, H. M., Fischer, K., Carcao, M., Chambost, H., Kenet, G., Kurnik, K., Königs, C., Male, C., Santagostino, E., & Ljung, R. (2019). Timing of inhibitor development in more than 1000 previously untreated patients with severe hemophilia A. Blood, 134(3), 317–320.
Orlova, N. A., Kovnir, S. V., Vorobiev, I. I., Gabibov, A. G., & Vorobiev, A. I. (2013). Blood Clotting Factor VIII: From Evolution to Therapy. Acta Naturae, 5(2), 19–39.
Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity. Science, 337(6096), 816–821.
Cong, L., Ran, F. A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P. D., Wu, X., Jiang, W., Marraffini, L. A., & Zhang, F. (2013). Multiplex Genome Engineering Using CRISPR/Cas Systems. Science, 339(6121), 819–823.
Sun, W., Ji, W., Hall, J. M., Hu, Q., Wang, C., Beisel, C. L., & Gu, Z. (2015). Self-assembled DNA nanoclews for the efficient delivery of CRISPR-Cas9 for genome editing. Angewandte Chemie (International Ed. In English), 54(41), 12029–12033.
Chen, H., Shi, M., Gilam, A., Zheng, Q., Zhang, Y., Afrikanova, I., Li, J., Gluzman, Z., Jiang, R., Kong, L.-J., & Chen-Tsai, R. Y. (2019). Hemophilia A ameliorated in mice by CRISPR-based in vivo genome editing of human Factor VIII. Scientific Reports, 9(1).
Han, J. P., Kim, M., Choi, B. S., Lee, J. H., Lee, G. S., Jeong, M., Lee, Y., Kim, E.-A., Oh, H.-K., Go, N., Lee, H., Lee, K. J., Kim, U. G., Lee, J. Y., Kim, S., Chang, J., Lee, H., Song, D. W., & Yeom, S. C. (2022). In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Science Advances, 8(3).
Doudna, J. A. (2020). The promise and challenge of therapeutic genome editing. Nature, 578(7794), 229–236.
Pedroso de Lima, M. C., Simões, S., Pires, P., Faneca, H., & Düzgüneş, N. (2001). Cationic lipid–DNA complexes in gene delivery: from biophysics to biological applications. Advanced Drug Delivery Reviews, 47(2-3), 277–294.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
